Assembly Biosciences (NASDAQ:ASMB) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report sent to investors on Monday morning,Benzinga reports.

Assembly Biosciences Stock Performance

Shares of ASMB opened at $11.12 on Monday. Assembly Biosciences has a 52 week low of $10.27 and a 52 week high of $19.93. The stock has a market capitalization of $70.68 million, a price-to-earnings ratio of -1.65 and a beta of 0.62. The stock has a fifty day moving average of $12.84 and a 200-day moving average of $15.09.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.75) by $0.18. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The business had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.05 million. As a group, equities analysts forecast that Assembly Biosciences will post -6.87 EPS for the current year.

Insider Activity at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the acquisition, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 5.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP increased its stake in shares of Assembly Biosciences by 16.5% in the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 2,098 shares during the period. JPMorgan Chase & Co. boosted its holdings in Assembly Biosciences by 5,137.3% in the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 3,442 shares during the last quarter. FMR LLC increased its position in Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 3,635 shares during the period. Palumbo Wealth Management LLC bought a new position in Assembly Biosciences during the 4th quarter worth approximately $180,000. Finally, Man Group plc acquired a new position in shares of Assembly Biosciences in the 4th quarter worth approximately $309,000. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.